Baudet M F, Esteva O, Dachet C, Jacotot B
Atherosclerosis. 1986 Oct;62(1):65-71. doi: 10.1016/0021-9150(86)90020-1.
A possible mechanism of action of probucol on low density lipoprotein uptake was examined in 7 type IIa hypercholesterolemic subjects. Probucol administration effectively lowered plasma cholesterol. Both apo B-associated cholesterol and HDL cholesterol were decreased but a great inter-patient variability was noted. Plasma triglycerides were unchanged and phospholipids decreased. The composition of the isolated LDL was unaffected. The LDL displaceable activity of reference [125I]LDL measured by competition assays in control fibroblasts, was increased in 3 subjects, decreased in 1 subject and unchanged in the other 3. No correlation was found between the change in apo B-associated cholesterol and the change in the in vitro catabolism of LDL of treated patients. The results did not allow a simple mechanism of action to be ascribed to the drug, but questioned the origin of the hypercholesterolemia.
在7名IIa型高胆固醇血症患者中研究了普罗布考对低密度脂蛋白摄取的可能作用机制。给予普罗布考可有效降低血浆胆固醇。与载脂蛋白B相关的胆固醇和高密度脂蛋白胆固醇均降低,但患者间存在很大差异。血浆甘油三酯未改变,磷脂降低。分离出的低密度脂蛋白的组成未受影响。通过竞争分析在对照成纤维细胞中测量的参考[125I]低密度脂蛋白的低密度脂蛋白置换活性,在3名受试者中增加,在1名受试者中降低,在其他3名受试者中未改变。在治疗患者中,与载脂蛋白B相关的胆固醇变化与低密度脂蛋白体外分解代谢变化之间未发现相关性。结果无法将药物的作用机制简单归因于此,但对高胆固醇血症的起源提出了质疑。